AI Summary
The French clinical trial identified that the combination of trabectedin and doxorubicin can improve survival for people with advanced leiomyosarcoma. This combination treatment resulted in an increased median survival time of 9 months. This finding suggests that this treatment should now be recommended as the initial treatment for this type of cancer.
Results from a French clinical trial have identified what experts say should now be the recommended initial treatment of advanced leiomyosarcoma. In the trial, the combination of trabectedin (Yondelis) and doxorubicin improved survival by a median of 9 months.